$12.58
Today
as of Jul 22, 16:47 ET
Last 30 days
Recent Press Releases & News
Climb Bio Insider Sold Shares Worth $406,979, According to a Recent SEC Filing
Climb Bio Reports Encouraging Phase 1b Results for Budoprutug in ITP
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
Overview
52-week range
$1.16
$12
100% of range
Avg surprise (last 3)
-17.3%
Avg reaction (last 2)
-5.2%
0% positive
Latest IV / EM
174%
EM ±39.7% · $13 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.20 | $-0.26 | +23.1% | +35.5% | -2.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.19 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.13 | $-0.19 | +31.6% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.31 | $-0.15 | -106.7% | — | -7.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.13 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.81 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.06 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.15 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.19 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | -$0.22 | -$0.13 | -69.2% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-15M | — | $-15M | $-11M | $-23M | — | $-12M | $-56M |
| Net income | $-14M | — | $-13M | $-9M | $-21M | — | $-9M | $-55M |
| EPS (diluted) | $-0.20 | — | $-0.19 | $-0.13 | $-0.31 | — | $-0.13 | $-1.81 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $8M | $36M | $26M | $23M | $29M | $87M | $146M | $223M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $113M | $106M | $91M | $87M | $100M | $155M | $198M | $226M |
| Total assets | $152M | $168M | $182M | $192M | $201M | $217M | $222M | $226M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $4M | $7M | $5M | $7M | $7M | $5M | $3M | $4M |
| Total equity | $148M | $160M | $177M | $186M | $193M | $212M | $219M | $222M |